Oncology

Latest News

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com
Midkine May Play Key Role in SCLC

July 24th 2025

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com
RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

July 24th 2025

David Nguyen, MD | Image Credit: Tufts Medicine
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

July 23rd 2025

G
In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

July 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
July 29th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 29th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Marie Parish, PharmD, BCOP, screenshot
August 22nd 2024

Using Cannabis as a Bridge for Symptom Management in Cancer

Laura Joszt, MA
Patients with cancer will never completely replace existing pain regimens, but cannabis could be used in conjunction, explained Marie Parish, PharmD, BCOP, a gastrointestinal oncology pharmacist with Mayo Clinic.
Psychologist holding arm of patient in support | Image credit: pressmaster - stock.adobe.com
August 21st 2024

Spouses of Patients With Cancer Face Elevated Suicide Risk, Study Finds

Pearl Steinzor
Spouses of patients with cancer face a significantly higher risk of suicide attempts and suicide death, especially within the first year of diagnosis, according to one study.
FDA approval | Image Credit: cartoon-stock.adobe.com
August 16th 2024

FDA Approves Durvalumab Combination Therapy for Resectable Early-Stage NSCLC

Pearl Steinzor
The newly approved treatment regimen demonstrated a significant reduction in recurrence risk in patients with resectable non–small cell lung cancer (NSCLC).
Andrew Hantel, MD
August 14th 2024

We Need to Lower Barriers to and Burdens of Trial Entry: Dr Andrew Hantel

Kyle Munz
Andrew Hantel, MD, Dana-Farber Cancer Institute, discusses factors contributing to disparities in oncology clinical trial enrollment.
AJMC
August 13th 2024

The Accelerated Approval Program for Oncology Drugs: Celebrating More Than 250,000 Life-Years Gained and Counting

Julie Patterson, PharmD, PhD John Michael O’Brien, PharmD, MPH Jonathan D. Campbell, PhD
This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA’s accelerated approval program for oncology drugs came to different conclusions.
FDA Approved
August 8th 2024

FDA Approves Denileukin Difitox for Refractory Cutaneous T-Cell Lymphoma

Julia Bonavitacola
Relapsed or refractory cutaneous t-cell lymphoma can be treated in adults with the new FDA approval of denileukin diftitox immunotherapy.
Brain tumor 3D illustration | Imaged credit: Dr_Microbe - stock.adobe.com
August 7th 2024

Vorasidenib Approved by FDA for Grade 2 IDH-Mutant Glioma

Pearl Steinzor
Vorasidenib becomes the first targeted therapy for grade 2 isocitrate dehydrogenase (IDH)–mutant glioma to receive FDA approval.
Medical mammogram exam | Image Credit: TeraVector - stock.adobe.com
August 6th 2024

COVID-19 Disrupted Breast Cancer Screenings, Exacerbated Disparities

Cameron Santoro
The COVID-19 pandemic disrupted breast cancer screenings, leading to decreased follow-up rates and widening health disparities.
3D illustration of ovarian cancer | Image Credit: Lars Neumann - stock.adobe.com
August 6th 2024

Patients With Endometriosis May Have Higher Ovarian Cancer Risk

Brooke McCormick
Patients with endometriosis have a 4.2-fold greater ovarian cancer risk, highlighting the need for further research into the biological links between endometriosis subtypes and ovarian cancer.
Lung cancer diagnosis | Image Credit: Vitalii Vodolazskyi-stock.adobe.com
August 1st 2024

NSCLC Study Highlights Need for Adjuvant Trials in Early-Stage Disease

Maggie L. Shaw
Visceral pleural invasion of non–small cell lung cancer (NSCLC) was investigated in this analysis for its potential to predispose patients to worse survival outcomes and greater chances of disease recurrence.
Amit Singal, MD, UT Southwestern Medical Center
August 1st 2024

Addressing Ongoing Disparities in Liver Cancer Care: Dr Amit Singal

Rose McNulty
Amit Singal, MD, medical director of the Liver Tumor Program and chief of hepatology at UT Southwestern Medical Center, discusses his research on disparities in hepatocellular carcinoma care in the US.
Pink ribbon for breast cancer. | Image Credit: Andrey Popov - stock.adobe.com
July 31st 2024

Black Women With Obesity, Elevated Leptin Levels at Higher Risk for Breast Cancer

Cameron Santoro
The risk of early-onset breast cancer, particularly luminal A and triple-negative subtypes, was higher in Black women with obesity and high leptin levels compared with White women. This research highlights the urgent need for targeted interventions to address racial disparities in breast cancer outcomes.
cancer patient enjoying life | Image credit: VadimGuzhva - stock.adobe.com
July 29th 2024

Protein Signatures Could Improve Patient Outcome Predictions in Soft Tissue Sarcomas

Skylar Jeremias
A study demonstrates the value of incorporating protein signatures in creating more advanced prediction tools for patient outcomes.
FDA | Image Credit: wladimir1804-stock.adobe.com
July 28th 2024

ODAC Votes to Require Trial Assessment of Neoadjuvant vs Adjuvant Benefits in Resectable NSCLC

Caroline Seymour
Should the FDA require that new trial design proposals for perioperative regimens for resectable non–small cell lung cancer (NSCLC) include adequate within trial assessment?
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
July 28th 2024

Addressing Drug Shortages: Enhancing Buffer Stock, Transparency to Mitigate Future Crises

Pearl Steinzor
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, discusses possible federal policies to help mitigate ongoing and future cancer drug shortages.
Female patient holding up breast cancer awareness ribbon | Image Credit: Pixel-Shot - stock.adobe.com
July 27th 2024

Study: Breast Cancer Immunotherapy Trials Make Modest Clinical Impact

Brooke McCormick
Despite numerous trials, breast cancer immunotherapies have had a modest clinical impact, with only 2 approved drugs, highlighting inefficiencies in the clinical trial system.
AI models can be useful tools for clinicians, helping assess risk in patients with HCC to inform disease management. | Image credit: ipopba - stock.adobe.com
July 26th 2024

AI Model Precisely Identifies HCC Recurrence Risk Factors

Rose McNulty
Artificial intelligence (AI) models have potential to help clinicians assess risk in patients with hepatocellular carcinoma (HCC) to inform disease management, a new study found.
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
July 25th 2024

Effective Solutions for Drug Shortages: Market Incentives, Infrastructure, and Quality Management

Pearl Steinzor
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, discusses different policy approaches to address the ongoing cancer drug shortage.
Mammogram screening | Image Credit: okrasiuk - stock.adobe.com
July 25th 2024

Risks, Benefits of Bilateral Mastectomy for Unilateral Breast Cancer

Cameron Santoro
Despite a significant increase in women with unilateral breast cancer who received a bilateral mastectomy, this study found no survival benefit compared with other treatment options. Although removing the unaffected breast reduces the risk of developing cancer in the other breast, results did not show decreased risk of death from breast cancer.
Colon | Image credit: New Africa - stock.adobe.com
July 24th 2024

Metabolic Dysfunction–Associated Steatotic Liver Disease Linked With CRC

Julia Bonavitacola
Patients diagnoesd with metabolic dysfunction–associated steatotic liver disease may have a higher risk of colorectal cancer (CRC) or colorectal adenoma.
dr diane mahoney
July 23rd 2024

Dr Diane Mahoney Uncovers Health Disparities Among Black, Hispanic Ovarian Cancer Survivors

Brooke McCormick
Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, discusses her study on how social determinants of health impact the health perceptions of Black and Hispanic ovarian cancer survivors, highlighting significant health disparities.
Illustration of liver cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
July 22nd 2024

Response to Immunotherapy Linked With Improved Liver Function in Advanced HCC

Rose McNulty
Although the amount of real-world evidence demonstrating the safety and efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma (HCC) has been growing, data on liver function evolution as a prognostic factor for overall survival are lacking.
STS word cloud | Image Credit: Colored Lights-stock.adobe.com
July 16th 2024

Pembrolizumab Promising in Treating Soft Tissue Sarcoma

Maggie L. Shaw
Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma.
Jessica K. Paulus, ScD, Ontada
July 13th 2024

Lung Cancer Detection Trends Show Shift in Pandemic Aftermath

Maggie L. Shaw
In this final segment of our interview with Ontada's Jessica K. Paulus, ScD, she explains how her team's data presented at the American Society of Clinical Oncology annual conference may translate to the real world.
Cancer risk infographic | girafchik - stock.adobe.com
July 11th 2024

New Study Reveals 40% of US Cancer Cases, Nearly Half of Deaths Linked to Modifiable Risk Factors

Pearl Steinzor
Cigarette smoking among other modifiable risk factors were significantly associated with cancer cases and deaths.
Prescription drugs illustration | Image credit: Commonwealth Fund
July 9th 2024

FTC Finds PBMs Drive Up Drug Costs, Squeeze Out Competitors

Mary Caffrey
A long-awaited report from the Federal Trade Commission (FTC) finds that vertical integration and consolidation have worked against consumers and independent pharmacies.
Ravin Ratan, MD< MEd, MD Anderson
July 8th 2024

Caring for Patients Is a Team Sport

Maggie L. Shaw
To conclude our interview with him, Ravin Ratan, MD, MEd, of MD Anderson, explains the importance of caring for all patients and why he tries to own the process of patients feeling confident that they received the attention they deserve.
Jessica K. Paulus, ScD, Ontada
Published: July 6th 2024 | Updated: July 1st 2024

COVID-19's Potential Impact on Advanced-Stage Lung Cancer Trends

Maggie L. Shaw
In our ongoing interview with Jessica K. Paulus, ScD, Ontada, she explains potential drivers behind changing trends in care for lung cancer that may have been influenced by the COVID-19 pandemic.
Michael A. Choti, MD, MBA
July 4th 2024

Dr Michael A. Choti: Integrated, Multidisciplinary Cancer Care Management Crucial for Value-Based Medicine

Kyle Munz
Michael A. Choti, MD, MBA, Banner MD Anderson, cochaired the second annual Advancing Value-Based Oncology Care meeting and shared insights into the goals of this year's event and value-based medicine as a whole.
FDA Approval word blocks | Image credit: Dzmitry - stock.adobe.com
July 3rd 2024

FDA Approves FoundationOne Liquid CDx as a Diagnostic Tool for BRCA-Mutated mCRPC

Alexandra Gerlach
FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC).
<1
...
456789101112
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo